Back to Authors

Holm, Marie‐Louise

https://orcid.org/0000-0002-2726-5311

Mayo Clinic

Department of Neuroscience,

Citations 4

LRP1 in vascular mural cells modulates cerebrovascular integrity and function in the presence of APOE4
Oue, Hiroshi , Yamazaki, Yu , Qiao, Wenhui , Yuanxin, Chen, Ren, Yingxue , Kurti, Aishe, Shue, Francis , Parsons, Tammee M., Perkerson, Ralph B., Kawatani, Keiji , Wang, Ni , Starling, Skylar C , Mosneag, Ioana‐Emilia , Aikawa, Tomonori , Holm, Marie‐Louise , Liu, Chia‐Chen , Inoue, Yasuteru , Sullivan, Patrick M. , Asmann, Yan W. , Bu, Guojun , Kanekiyo, Takahisa , Liu, Chia-Chen , Bu, Guojun , Shue, Francis , Yuanxin, Chen, Roy, Bhaskar, Kim, Betty Y.S. , Yamazaki, Yu

JCI Insight | April 9, 2023 | Volume: 8 | Issue: 7 | Pages: No page available

10.1172/jci.insight.163822 Get It

Cerebrovasculature is critical in maintaining brain homeostasis; its dysregulation often leads to vascular cognitive impairment and dementia (VCID) during aging. VCID is the second most prevalent cause of dementia in the elderly, after Alzheimer’s disease (AD), with frequent cooccurrence of VCID and AD. While multiple factors are involved in the pathogenesis of AD and VCID, APOE4 increases the risk for both diseases. A major apolipoprotein E (apoE) receptor, the low-density lipoprotein receptor-related protein 1 (LRP1), is abundantly expressed in vascular mural cells (pericytes and smooth muscle cells). Here, we investigated how deficiency of vascular mural cell LRP1 affects the cerebrovascular system and cognitive performance using vascular mural cell–specific Lrp1 -KO mice ( smLrp1 –/– ) in a human APOE3 or APOE4 background. We found that spatial memory was impaired in the 13- to 16-month-old APOE4 smLrp1 –/– mice but not in the APOE3 smLrp1 –/– mice, compared with their respective littermate control mice. These disruptions in the APOE4 smLrp1 –/– mice were accompanied with excess paravascular glial activation and reduced cerebrovascular collagen IV. In addition, blood-brain barrier (BBB) integrity was disrupted in the APOE4 smLrp1 –/– mice. Together, our results suggest that vascular mural cell LRP1 modulates cerebrovasculature integrity and function in an APOE genotype–dependent manner.
Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease
Liu, Chia‐Chen , Martens, Yuka A. , Jia, Lin , Yamazaki, Akari, Diehl, Nancy N. , Zhao, Na , DeTure, Michael , Davis, Mary Dabney , Felton, Lindsey M., Qiao, Wenhui , Li, Yonghe , Li, Hongmei , Wang, Na , Wren, Melissa C. , Aikawa, Tomonori , Holm, Marie‐Louise , Allen, Mariet , Carrasquillo, Minerva M. , Murray, Melissa E. , Petersen, Ronald C. , Ertekin‐Taner, Nilüfer , Kanekiyo, Takahisa , Bu, Guojun , Wren, Melissa, Oue, Hiroshi , Linares, Cynthia , Liu, Chia-Chen , Bu, Guojun , Murray, Melissa E , Zhao, Na , Yamazaki, Yu , Heckman, Michael G. , Zhao, Jing , Davis, Mary D., Fu, Yuan , Oue, Hiroshi, Carrasquillo, Minerva M. , Dickson, Dennis W.

Alzheimer's & Dementia | August 22, 2020 | Volume: 16 | Issue: 10 | Pages: 1372-1383

10.1002/alz.12104 Get It

AbstractIntroductionCerebrovascular pathologies including cerebral amyloid angiopathy (CAA) and blood‐brain barrier (BBB) dysregulation are prominent features in the majority of Alzheimer's disease (AD) cases.MethodsWe performed neuropathologic and biochemical studies on a large, neuropathologically confirmed human AD cohort (N = 469). Amounts of endothelial tight junction proteins claudin‐5 (CLDN5) and occludin (OCLN), and major AD‐related molecules (amyloid beta [Aβ40], Aβ42, tau, p‐tau, and apolipoprotein E) in the temporal cortex were assessed by ELISA.ResultsHigher levels of soluble tau, insoluble p‐tau, and apolipoprotein E (apoE) were independently correlated with lower levels of endothelial tight junction proteins CLDN5 and OCLN in AD brains. Although high Aβ40 levels, APOE ε4, and male sex were predominantly associated with exacerbated CAA severity, those factors did not influence tight junction protein levels.DiscussionRefining the molecular mechanisms connecting tau, Aβ, and apoE with cerebrovascular pathologies is critical for greater understanding of AD pathogenesis and establishing effective therapeutic interventions for the disease.
ABCA7 haplodeficiency disturbs microglial immune responses in the mouse brain
Aikawa, Tomonori , Ren, Yingxue , Tachibana, Masaya , Johnson, Madeleine R., Anderson, Casey T., Martens, Yuka A. , Holm, Marie‐Louise , Asmann, Yan W. , Saito, Takashi , Fitzgerald, Michael L. , Bu, Guojun , Kanekiyo, Takahisa , Bu, Guojun , Aikawa, Tomonori , Yamazaki, Yu , Saido, Takaomi C.

Proceedings of the National Academy of Sciences | November 5, 2019 | Volume: 116 | Issue: 47 | Pages: 23790-23796

10.1073/pnas.1908529116 Get It

Carrying premature termination codons in 1 allele of the ABCA7 gene is associated with an increased risk for Alzheimer’s disease (AD). While the primary function of ABCA7 is to regulate the transport of phospholipids and cholesterol, ABCA7 is also involved in maintaining homeostasis of the immune system. Since inflammatory pathways causatively or consequently participate in AD pathogenesis, we studied the effects of Abca7 haplodeficiency in mice on brain immune responses under acute and chronic conditions. When acute inflammation was induced through peripheral lipopolysaccharide injection in control or heterozygous Abca7 knockout mice, partial ABCA7 deficiency diminished proinflammatory responses by impairing CD14 expression in the brain. On breeding to App NL-G-F knockin mice, we observed increased amyloid-β (Aβ) accumulation and abnormal endosomal morphology in microglia. Taken together, our results demonstrate that ABCA7 loss of function may contribute to AD pathogenesis by altering proper microglial responses to acute inflammatory challenges and during the development of amyloid pathology, providing insight into disease mechanisms and possible treatment strategies.
ABCA7 and Pathogenic Pathways of Alzheimer’s Disease
Aikawa, Tomonori , Holm, Marie‐Louise , Kanekiyo, Takahisa , Aikawa, Tomonori

Brain Sciences | February 5, 2018 | Volume: 8 | Issue: 2 | Pages: 27

10.3390/brainsci8020027 Get It

The ATP-binding cassette (ABC) reporter family functions to regulate the homeostasis of phospholipids and cholesterol in the central nervous system, as well as peripheral tissues. ABCA7 belongs to the A subfamily of ABC transporters, which shares 54% sequence identity with ABCA1. While ABCA7 is expressed in a variety of tissues/organs, including the brain, recent genome-wide association studies (GWAS) have identified ABCA7 gene variants as susceptibility loci for late-onset Alzheimer’s disease (AD). More important, subsequent genome sequencing analyses have revealed that premature termination codon mutations in ABCA7 are associated with the increased risk for AD. Alzheimer’s disease is a progressive neurodegenerative disease and the most common cause of dementia, where the accumulation and deposition of amyloid-β (Aβ) peptides cleaved from amyloid precursor protein (APP) in the brain trigger the pathogenic cascade of the disease. In consistence with human genetic studies, increasing evidence has demonstrated that ABCA7 deficiency exacerbates Aβ pathology using in vitro and in vivo models. While ABCA7 has been shown to mediate phagocytic activity in macrophages, ABCA7 is also involved in the microglial Aβ clearance pathway. Furthermore, ABCA7 deficiency results in accelerated Aβ production, likely by facilitating endocytosis and/or processing of APP. Taken together, current evidence suggests that ABCA7 loss-of-function contributes to AD-related phenotypes through multiple pathways. A better understanding of the function of ABCA7 beyond lipid metabolism in both physiological and pathological conditions becomes increasingly important to explore AD pathogenesis.